DOW JONES23,433.57+779.71 3.44%
S&P 5002,749.98+90.57 3.41%
NASDAQ8,090.90+203.64 2.58%

Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $34

Credit Suisse analyst Tiago Fauth maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $36 to $34.

Benzinga · 03/02/2020 12:42

Credit Suisse analyst Tiago Fauth maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $36 to $34.